echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Why do I get seriously ill after contracting the virus? Immune bias and failure or main cause

    Why do I get seriously ill after contracting the virus? Immune bias and failure or main cause

    • Last Update: 2020-12-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Science and Technology Daily (reporter
    ) infected with the new coronavirus, why do some people get seriously ill, and some people don't? This has always been an unsolt mystery. Now, writing in the latest issue of science, scientists say their latest study finds that perhaps immune bias and failure are causing the difference between severe and mild cases in patients with neo-coronary pneumonia.
    explained that this immune bias may stem from the different responses of our innate immune system to the new coronavirus. From fruit flies to humans, all organisms have an innate immune system that quickly senses viruses and other pathogens. Once viruses are detected, the innate immune system immediately attacks them without distinction, mobilizing "sharpshooter" cells that can strike more precisely but at a slower rate, which belong to another branch of the body's pathogen defense system, the adaptive immune system.
    researchers analyzed the immune responses of 76 patients with neo-coronary pneumonia and 69 healthy people. They found an increase in molecular concentrations that promote inflammatory responses in the blood in patients with severe coronary pneumonia, and identified three molecules that were also associated with inflammation in other lungs.
    researchers believe the three molecules and their subjects may be targets for the treatment of neo-coronary pneumonia, and they are testing the therapeutic potential of blocking these molecules in animal models of new coronary pneumonia.
    Scientists have also found that the concentration of bacterial fragments in the blood of patients with severe coronary pneumonia, such as bacterial DNA and cell wall materials, increases, and that the more fragments there are, the more severe the patient's condition and the more inflammatory substances circulating in the blood, Physicist.com reported. Moreover, in patients with severe coronary pneumonia, bacterial products, usually found only in the intestines, lungs and throat, can enter the bloodstream, enhancing the inflammatory response and spreading through the circulatory system to all parts of the body.
    study also found that as the disease worsened, key cells in the innococcal immune system in the blood of patients with neo-coronary pneumonia did not act because of the presence of viruses or bacteria, but were slow to respond.
    , senior author of the study and a senior author of the study, said: "These findings shed light on how the immune system goes wrong during a new coronavirus infection, causing serious illness, and identify potential therapeutic targets. "
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.